Preview

Рецепт

Расширенный поиск

Перспективы использования лекарственного растительного сырья в наружных формах противовоспалительного действия

https://doi.org/10.34883/PI.2021.24.1.006

Полный текст:

Аннотация

Воспаление – один из самых частых патофизиологических процессов, встречающихся при заболеваниях опорно-двигательного аппарата, поэтому поиск и разработка лекарственных средств противовоспалительного действия является перспективным научным направлением. В статье рассмотрена характеристика лекарственных растений, обладающих противовоспалительным потенциалом, приведен компонентный состав данных растений, указаны компоненты, отвечающие за противовоспалительную активность, и возможный механизм их действия. Описаны примеры in vitro и in vivo исследований противовоспалительной активности календулы лекарственной, окопника лекарственного, полыни горькой, зверобоя продырявленного и тысячелистника обыкновенного. Приведены наружные лекарственные средства на растительной основе, обладающие противовоспалительным действием, зарегистрированные в Республике Беларусь.

Об авторах

О. А. Сушинская
Белорусский государственный медицинский университет
Беларусь


Н. С. Голяк
Белорусский государственный медицинский университет
Беларусь


Список литературы

1. Titova N.G. (2016) Tekhnologiya polucheniya preparatov na osnove kalenduly lekarstvennoj (Calendula officinalis) [Technology of producing medicines on the base of calendula officinalis]. Farmacevticheskij byulleten’, no 1–2, pp. 120–132.

2. Muley B.P., Khadabadi S.S., Banarase N.B. (2009) Phytochemical constituents and pharmacological activities of Calendula officinalis linn (Asteraceae): A review. Tropical Journal of Pharmaceutical Research, vol. 8, no 5, pp. 455–465.

3. Dawid-Pac R. (2013) Medicinal plants used in treatment of inflammatory skin diseases. Adv in Derm and Allerg, vol. 3, pp. 170–177.

4. (2002) WHO Monographs on selected medicinal plants. Vol. 2. Flos Calendulae. World Health Organization, Geneva, pp. 35–44.

5. Zitterl-Eglseer K., Reznicek G., Jurenitsch J. (2001) Morphogenetic variability of faradiol monoesters in marigold Calendula officinalis L.Phytochemical Analysis, vol. 12, no 3, pp. 199–201.

6. European Scientific Cooperative on Phytotherapy (2019). ESCOP monographs, The Scientific Foundation for Herbal Medicinal Products. Online series. Calendulae flos (Calendula flower).

7. Ukiya M., Akihisa T., Yasukava K. (2006) Anti-inflammatory, anti-tumor-promoting and cytotoxic activities of constituents of marigold (Calendula officinalis) flowers. J Nat Prod, vol. 69, pp. 1692–1696.

8. Della L.R. (1990) Topical anti-inflammatory activity of Calendula officinalis extracts. Planta Med, vol. 56, pp. 658–658.

9. Della L.R., Tubaro A., Sosa S. (1994) The role of triterpenoids in topical anti-inflammatory activity of Calendula officinalis flowers. Planta Med, vol. 60, pp. 516–520.

10. Bezakova L., Masterova I., Paulikova I. (1996) Inhibitory activity of isorhamnetinglycosides from Calendula officinalis L. on the activity of lipoxygenase. Pharmazie, vol. 51, no 2, pp. 126–127.

11. Zitterl-Eglseer K., Sosa S., Jurenitsch J. (1997) Anti-oedematous activities of the main triterpendiol esters of marigold (Calendula officinalis L.).J Ethnopharmacol, vol. 57, no 2, pp. 139–144.

12. Szopa A., Pajor J., Klin P. (2020) Artemisia absinthium L. Importance in the history of medicine, the latest advances in phytochemistry and therapeutical, cosmetological and culinary uses. Plants, vol. 1063, no 9, pp. 1–33.

13. Ahamad J., Mir S.R., Amin S.A. (2019) Pharmacognostic review on Artemisia absinthium. Int. Res. J. Pharm, vol. 10, pp. 25–31.

14. Batiha G.E.-S., Olatunde A., El-Mleeh A. (2020) Bioactive compounds, pharmacological actions, and pharmacokinetics of wormwood (Artemisia absinthium). Antibiotics, vol. 353, no 9, pp. 1–25.

15. Nalbantsoy A., Erel S.B., Köksal C. (2013) Viper venom induced inflammation with Montivipera xanthina (Gray, 1849) and the anti‐snake venom activities of Artemisia absinthium L. in rat. Toxicon, vol. 65, pp. 34–40.

16. Lee H.G., Kim H., Oh W.K. (2004) Tetramethoxy hydroxyflavone p7F down regulates inflammatory mediators via the inhibition of nuclear factor kB. Ann. N.Y. Acad. Sci, vol. 1030, pp. 555–568.

17. Hatziieremia S., Gray A., Ferro V. (2006) The effects of cardamonin on lipopolysaccharide induced inflammatory protein production and MAP kinase and NFkB signaling pathways in monocytes/macrophages. Br. J. Pharm, vol. 149, pp. 188–198.

18. Zeng K.W., Liao L.X., Song X.M. (2015) Caruifolin D from Artemisia absinthium L. inhibits neuroinflammation via reactive oxygen species‐ dependent c‐jun N-terminal kinase and protein kinase c/NF‐kB signaling pathways. Eur. J. Pharmacol, vol.767, pp. 82–93.

19. Choi S.C., Choi E.J., Oh H.M. (2006) DA-9601 a standardized extract of Artemisia asiatica, blocks TNF‐α‐induced IL‐8 and CCL20 production by inhibiting p38 kinase and NF‐κB pathways in human gastric epithelial cells. World J. Gastroenterol, vol. 30, no 12, pp. 4850–4858.

20. Basiri Z., Zeraati F., Ashari F. (2017) Topical effects of Artemisia absinthium ointment and liniment in comparison with piroxicam gel in patients with knee joint osteoarthritis: A randomized double-blind controlled trial. Iran J Med Sci, vol. 42, no 6, pp. 524–531.

21. Staiger C. (2012) Comfrey: A clinical overview. Phytother Res, vol. 26, no 10, pp. 1441–1448.

22. Orloveckaya N.F., Dankevich O.S. (2016) Okopnik lekarstvennyj – perspektivnoe rastenie dlya sozdaniya novyh lekarstvennyh preparatov. Teoret ta prakt aspekti doslіdzh lіkars’kih roslin (Harkіv, 21–23 berez., NFaU) [Symphytum officinale is a promising plant for creation of new drugs. Theoretical and practical aspects of the studies of medicinal plants]. Harkiv: NfaU, pp. 189–191. (in Russian)

23. Salehi B., Sharopov F., Boyunegmez T. (2019) Symphytum species: A comprehensive review on chemical composition, food applications and phytopharmacology. Molecules, vol. 24, no 2272, pp. 1–33.

24. Seigner J., Junker-Samek M., Plaza A. (2019) A Symphytum officinale root extract exerts anti-inflammatory properties by affecting two distinct steps of NF-κB signaling. Front Pharmacol., vol. 10, no 289, pp. 1–12.

25. (2009) European Scientific Cooperative on Phytotherapy. Symphyti radix. 2nd ed. Supplement. New York: Thieme. ESCOP Monographs; pp. 249–254.

26. Hiermann A., Writzel M. (1998) Antiphlogistic glycopeptide from the roots of Symphytum officinale. Pharm. Pharmacol. Lett., vol. 8, pp. 154–157.

27. Vostinaru O., Conea S., Mogosan C. (2018) Anti-inflammatory and antinociceptive effect of Symphytum officinale root. Rom. Biotechnol. Lett., vol. 23, no 6, pp. 14160–14167.

28. Al-Snafi A.E. (2013) Chemical constituents and pharmacological activities of milfoil (Achillea santolina). A review. Int J Pharm Tech Res, vol. 5, pp. 1373–1377.

29. Nemeth E., Bernath J. (2008) Biological activities of yarrow species (Achillea spp.). Current Pharmaceutical Design, vol. 14, pp. 3151–3167.

30. (2009) European Scientific Cooperative on Phytotherapy. Millefolii herba. 2nd ed. Supplement. New York: Thieme. ESCOP Monographs; pp. 175–183.

31. EMEA. European Medicines Agency Achillea millefolium L., Herba; London: 2009.

32. Tadić V., Arsić I., Zvezdanović J. (2017) The estimation of the traditionally used yarrow (Achillea millefolium L. Asteraceae) oil extracts with anti- inflammatory potential in topical application. Journal of Ethnopharmacology, vol. 199, pp. 138–148.

33. Maswadeh H.M., Semreen M.H., Naddaf A.R. (2006) Anti-inflammatory activity of Achillea and Ruscus topical gel on carrageenan-induced paw edema in rats. Acta Pol Pharm, vol. 63, no 4, pp. 277–280.

34. Tekieh E., Akbari A., Manaheji H. (2011) Anti-hyperalgesic and anti-inflammatory effects of Achillea santolina and Stachys athorecalyx extracts on complete Freund’s adjuvant–induced short-term inflammation in male wistar rats. Koomesh, vol. 12, no 3, pp. 305–313.

35. Gomez M.A., Saenz M.T., Garcia M.D. (1999) Study of the topical anti-inflammatory activity of Achillea ageratum on chronic and acute inflammation models. Zeitschrift Für Naturforschung C, vol. 54, no 11, pp. 937–941.

36. WHO. Herba Hyperici. Geneva: World Health Organization; 2002. Monographs on selected medicinal plants; pp. 149–171.

37. European Scientific Cooperative on Phytotherapy. Hyperici herba. 2nd ed. Supplement. New York: Thieme; 2009. ESCOP Monographs. pp. 1–3.

38. Sosa S., Pace R., Bornancin A. (2010) Topical anti-inflammatory activity of extracts and compounds from Hypericum perforatum L. J Pharmacy Pharmacol, vol. 59, no 5, pp. 703–709.

39. Schempp C.M., Lüdtke R., Winghofer B. (2000) Effect of topical application of Hypericum perforatum extract (St. John’s wort) on skin sensitivity to solar simulated radiation. Photodermatol Photoimmunol Photomed, vol. 16, no 3, pp. 125–128.

40. Kumar V., Singh P.N., Bhattacharya S.K. (2001) Anti-inflammatory and analgesic activity of Indian Hypericum perforatum L. Indian J Exp Biol, vol. 39, no 4, pp. 339–343.

41. Reestr lekarstvennih sredstv Respubliki Belarus’ [Register of medicines of the Republic of Belarus]. Reestri UP “Tsentr ekspertiz i ispitanii v zdravoohranenii”. Available at: http://www.rceth.by/Refbank/


Для цитирования:


Сушинская О.А., Голяк Н.С. Перспективы использования лекарственного растительного сырья в наружных формах противовоспалительного действия. Рецепт. 2021;(1):67-77. https://doi.org/10.34883/PI.2021.24.1.006

For citation:


Sushinskaya .O., Golyak .N. Prospects of Use of Herbal Raw Materials in External Dosage Forms of Anti-Inflammatory Action. Recipe. 2021;(1):67-77. (In Russ.) https://doi.org/10.34883/PI.2021.24.1.006

Просмотров: 29


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1993-4882 (Print)
ISSN 2414-2263 (Online)